Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lipoprotein (a): a new cardiovascular risk factor].

C Herbaut1

  • 1Service de Médecine Interne, C.I.U. Ambroise Paré, Mons.

Revue Medicale De Bruxelles
|May 1, 1991
PubMed
Summary

Lipoprotein(a) [Lp(a)] is an atherogenic particle linked to cardiovascular risk. Further research is needed to understand Lp(a) metabolism and its precise role in atherosclerosis development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Cytochemical and ultrastructural study of oogenesis inLithobius forficatus L. (Myriapoda, Chilopoda). Evolution of cellular components].

Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen·2017
Same author

Pearl formation: persistence of the graft during the entire process of biomineralization.

Marine biotechnology (New York, N.Y.)·2006
Same author

[Omega-3 and health].

Revue medicale de Bruxelles·2006
Same author

[Recent oral antidiabetic therapy].

Revue medicale de Bruxelles·2005
Same author

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.

Research communications in molecular pathology and pharmacology·1999
Same author

Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension.

The American journal of medicine·1992

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Molecular Biology

Context:

  • Lipoprotein(a) [Lp(a)] is a distinct lipoprotein particle composed of low-density lipoprotein (LDL) and apolipoprotein(a) (apo(a)).
  • Apolipoprotein(a) shares structural similarities with plasminogen, a key protein in the blood clotting cascade.
  • Clinical evidence suggests Lp(a) possesses significant atherogenic properties, contributing to the development of atherosclerosis.

Purpose:

  • To elucidate the metabolic pathways of Lipoprotein(a) [Lp(a)].
  • To identify the specific mechanisms underlying the atherogenic effects of Lp(a).

Summary:

  • Lp(a) is an LDL particle with an attached apo(a) glycoprotein.
  • Apo(a) shares features with plasminogen, hinting at potential roles in both lipid metabolism and thrombosis.
  • Despite clinical data indicating atherogenicity, the exact metabolism and causative mechanisms of Lp(a) remain largely unknown.

Impact:

  • Understanding Lp(a) metabolism and atherogenic mechanisms is crucial for accurate cardiovascular risk assessment.
  • Widespread Lp(a) measurement could significantly enhance the prediction and management of cardiovascular diseases.
  • This knowledge gap highlights the need for further investigation into Lp(a) as a therapeutic target.

Related Experiment Videos